61 results about "Calcitonin gene-related peptide" patented technology

Topically applicable pharmaceutical/dermatological/cosmetic compositions well suited for the therapeutic treatment or care of sensitive human skin, hair, mucous membranes, nails and/or the scalp, in particular for reducing or avoiding the skin-irritant side effects of a variety of bioactive agents, for example the alpha -hydroxy acids, comprise a therapeutically/cosmetically effective amount of at least one calcitonin gene related peptide ("CGRP") antagonist, e.g., CGRP 8-37 or an anti-CGRP antibody.

This invention relates to a method for the biochemical treatment of persistent pain disorders by inhibiting the biochemical mediators of inflammation in a subject comprising administering to said subject any one of several combinations of components that are inhibitors of biochemical mediators of inflammation. Said process for biochemical treatment of persistent pain disorders is based on Sota Omoigui's Law, which states: ‘The origin of all pain is inflammation and the inflammatory response’. Sota Omoigui's Law of Pain unifies all pain syndromes as sharing a common origin of inflammation and the inflammatory response. The various biochemical mediators of inflammation are present in differing amounts in all pain syndromes and are responsible for the pain experience. Classification and treatment of pain syndromes should depend on the complex inflammatory profile. A variety of mediators are generated by tissue injury and inflammation. These include substances produced by damaged tissue, substances of vascular origin as well as substances released by nerve fibers themselves, sympathetic fibers and various immune cells. Biochemical mediators of inflammation that are targeted for inhibition include but are not limited to: prostaglandin, nitric oxide, tumor necrosis factor alpha, interleukin 1-alpha, interleukin 1-beta, interleukin-4, Interleukin-6 and interleukin-8, histamine and serotonin, substance P, Matrix Metallo-Proteinase, calcitonin gene-related peptide, vasoactive intestinal peptide as well as the potent inflammatory mediator peptide proteins neurokinin A, bradykinin, kallidin and T-kinin.

Healing of wounds in mammalian tissue may be enhanced by the application of certain neuropeptides, optionally in combination with known growth promoting hormones. Exemplary neuropeptides include tachykinins, such as Substance P, Substance K, and the like, as well as calcitonin gene-related peptides. The compositions may further include a polymeric delivery carrier and are utilized by applying to the site of the wound. Wounds may be vascular or avascular wounds. The compositions promote elaboration of cellular matrices and development of cellular attachment mechanisms in addition to stimulating cellular proliferation.

The invention features methods for preventing or treating visceral pain, including pain associated with functional bowel disorder, inflammatory bowel disease and interstitial cystitis, by administering an anti-CGRP antagonist antibody.

The invention features methods for preventing or treating CGRP associated disorders such as vasomotor symptoms and/or headaches (e.g., migraine, cluster headache, and tension headache) by administering an anti-CGRP antagonist antibody. Compositions for use in the disclosed methods are also provided. Antagonist antibody G1 and antibodies derived from G1 directed to CGRP are also described.

The invention provides a fusion polypeptide transgene sequence for calcitonin-gene-related peptide and salmon calcitonin and a transgene engineering strain thereof, and relates to a fusion polypeptide transgene sequence and a transgene engineering strain. The invention solves the problem that: the prior calcitonin-gene-related peptide and salmon calcitonin fusion polypeptide are not suitable for industrialized production with microbes and animals as reactors. The calcitonin-gene-related peptide and salmon calcitonin fusion polypeptide transgene sequence is shown as SEQ ID NO.1. The calcitonin-gene-related peptide and salmon calcitonin fusion polypeptide transgene engineering strain is an agrobacterium containing fusion gene plasmids, wherein the fusion genes in the plasmids are shown as SEQ ID NO.1. The calcitonin-gene-related peptide and salmon calcitonin fusion polypeptide transgene engineering strain can be used for mediating a plant with the cost of the engineering strain being 1/10 to 1/50 of that of bacillus coli.

The invention provides calcitonin gene-related peptide and salmon calcitonin fusion polypeptide, relating to fusion polypeptide. In order to generate a product containing both calcitonin and the calcitonin gene-related peptide, the invention provides the calcitonin gene-related peptide and the salmon calcitonin fusion polypeptide. The amino acid sequence of the calcitonin gene-related peptide and the salmon calcitonin fusion polypeptide is shown in SEQ ID No:1; moreover, C-terminal amidation is carried out to the calcitonin gene-related peptide and the salmon calcitonin fusion polypeptide. Experiments verify that the calcitonin gene-related peptide and the salmon calcitonin fusion polypeptide preserve respective activities of the calcitonin gene-related peptide and salmon calcitonin.

The embodiments provide a modified calcitonin gene-related peptide antagonist including an N-terminal fragment of modified calcitonin gene-related peptide or related protein family member where at least two residues of the N-terminal fragment are cysteine (Cys) and at least one amino acid comprises a non-threonine substitution of a threonine (Thr) residue; a central core where the central core comprises an oc-helix; and a C-terminal fragment of modified calcitonin gene-related peptide or related protein family member comprising a C-terminal amide and where at least one amino acid of the C-terminal fragment is phenylalanine (Phe), proline (Pro), tyrosine (Tyr) or hydroxyproline (Hyp) or pharmaceutically acceptable salt thereof, as well as compositions, including pharmaceutical compositions, comprising a subject peptide. The embodiments further provide treatment methods, including methods of treating a migraine, the methods generally involving administering to an individual in need thereof an effective amount of a subject peptide or composition.

The invention discloses a medicine for treating protrusion of lumbar intervertebral disc. The raw material medicines including unprocessed radix astragali, centipede, scorpio, pangolin scales, eucommia ulmoides, dipsacus root, honeysuckle, zaocys dhumnade, Chinese angelica, radix paeoniae rubra, frankincense, myrrh, rhizoma corydalis, fructus psoraleae, rhizoma drynariae, radix clematidis, uncaria rhynchophylla, caulis sinomenii, kadsura pepper stem, caulis spatholobi, radix asparagi and radix ophiopogonis are ground into powder. The medicine disclosed by the invention has the functions of tonifying qi, invigorating kidney, dredging muscles, strengthening bone, activating blood, resolving stasis and dredging collaterals and relieving pain, realizes both dredging and replenishment and treatment on both symptoms and root causes when used for treating protrusion of lumbar intervertebral disc. According to the observation of the clinical curative effect on 300 patients, the total effective rate is 98%; and animal experiments indicate that the medicine disclosed by the invention obviously improves the IL-1 and CGRP (Calcitonin Gene-Related Peptide) in the serum of rat of a model for protrusion of lumbar intervertebral disc, and can remarkably improve the threshold of mechanical stimulus pain of the rat of the model for protrusion of lumbar intervertebral disc.

Disclosed are a method and a corresponding pharmaceutical composition for treating damaged ligaments. Neurogenic compounds in general and neuropeptides in particular have been found to be highly effective in stimulated repair of ligaments damaged due to traumatic injury, ligament disease, and disuse. Preferred active ingredients for use in the method and corresponding pharmaceutical composition include calcitonin gene-related peptide (CGRP), cholecystokinin (CCK), dynorphin, enkephalin, galanin, neuropeptide Y (NPY), neurotensin, somatostatin, substance P (SP), thyrotropin-releasing hormone (TRH), vasoactive intestinal peptide (VIP).

The invention provides application of rhizoma chuanxiong total alkaloid to preparation of a medicine for treating headache. According to the application provided by the invention, the rhizoma chuanxiong total alkaloid can be used for improving the content of 5-HT (5-hydroxytryptamine), 5-HIAA (5-Hydroxyindole Acetic Acid), ET (Endothelin), NA (Neuramidinase) and DA (Dopamine) in blood plasma and brain tissues of patients with the headache and reducing a CGRP (Calcitonin Gene-Related Peptide) level in the blood plasma and the brain tissues; the rhizoma chuanxiong total alkaloid can be used foreffectively treating the headache and has a good clinical application prospect.

The present invention discloses methods to prevent and treat cardiovascular disorders, hi certain aspects the methods are drawn to releasing endogenous calcitonin-gene related peptide from intrinsic cardiac adrenergic cells within the heart. In further aspects, a combination of a β₂ adrenergic receptor agonist β₂-AR agonist) and a vasodilator can be used in treating reperfusion injury.